Shenzhen Neptunus Bioengineering Co

Shenzhen Neptunus Bioengineering Co Long-term Debt

The Long-Term Debt of Shenzhen Neptunus Bioengineering Co (000078.SZ) as of Oct 28, 2026 is 361.64 M CNY. In the previous year, Long-Term Debt was 229.80 M CNY — a change of 57.37% (higher).

Long-term Debt

361.64 MCNY

YoY

57.37%

Last updated:

Long-Term Debt of Shenzhen Neptunus Bioengineering Co is 2025 361.64 M CNY. Long-Term Debt of Shenzhen Neptunus Bioengineering Co was 2024 229.80 M CNY. It decreases by 57.37% higher compared to the previous year.

The Shenzhen Neptunus Bioengineering Co Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2018
3.37 B CNY
Jan 1, 2019
1.36 B CNY
Jan 1, 2020
160.57 M CNY
Jan 1, 2021
223.16 M CNY
Jan 1, 2022
287.23 M CNY
Jan 1, 2023
200.42 M CNY
Jan 1, 2024
229.80 M CNY
Jan 1, 2025
361.64 M CNY
The Shenzhen Neptunus Bioengineering Co Long-term Debt history
YEARLong-term DebtYoY
361.64 MCNY+57.37%
229.80 MCNY+14.66%
200.42 MCNY-30.22%
287.23 MCNY+28.71%
223.16 MCNY+38.98%
160.57 MCNY-88.20%
1.36 BCNY-59.69%
3.37 BCNY+98.18%
1.70 BCNY+6,901.05%
24.32 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shenzhen Neptunus Bioengineering Co Stock analysis

What does Shenzhen Neptunus Bioengineering Co do? Shenzhen Neptunus Bioengineering Co., Ltd. generates revenue through its pharmaceutical products and healthcare offerings. The company produces anti-tumor products, cardiovascular drugs, marine drugs, respiratory drugs, anti-infective products, and other pharmaceuticals. It also sells healthcare products, health food, and medical instruments. The primary market for these products is the domestic market, with East China being the main regional focus. The company serves healthcare providers, hospitals, and consumers within China's pharmaceutical sector. Neptunus targets the Chinese domestic market, emphasizing East China as its core region. Its product portfolio spans multiple therapeutic areas including oncology, cardiology, respiratory care, and infection control. The company's distribution network focuses on reaching hospitals and healthcare facilities across China, particularly in the East China region. The firm's health food and medical instrument lines complement its pharmaceutical business, creating diversified revenue streams within the healthcare industry. The business model relies on selling established pharmaceutical products alongside healthcare and medical solutions. Anti-tumor products and cardiovascular drugs form key segments of its revenue, supported by marine drugs and respiratory medications. East China's dominance in sales reflects the company's strategic market focus. The company's full-time employee count of 9,874 supports its manufacturing and distribution operations across China's domestic market. Shenzhen Neptunus Bioengineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shenzhen Neptunus Bioengineering Co stock

Long-Term Debt of Shenzhen Neptunus Bioengineering Co is 361.64 M CNY in 2025.

Long-Term Debt of Shenzhen Neptunus Bioengineering Co changed from 229.80 M CNY to 361.64 M CNY, representing a 57.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Shenzhen Neptunus Bioengineering Co since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Shenzhen Neptunus Bioengineering Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Shenzhen Neptunus Bioengineering Co

All Key Metrics — Shenzhen Neptunus Bioengineering Co